Tapering biologics noninferior to continuation in RA with sustained low activity

A 24-week multicenter randomized noninferiority trial compared stepwise tapering of biologic or targeted synthetic DMARDs against continued stable dosing in rheumatoid arthritis patients who had maintained low disease activity for at least six months. The trial reported that low disease activity was maintained in 89.6% of the continuation group versus 88.2% of the tapering group, meeting the prespecified noninferiority criterion, with most patients who worsened regaining low disease activity after protocol-guided reescalation; some disease activity measures at weeks 12 and 24 favored continuation, and adverse events were uncommon in both groups.

Most relevant for: Patients with rheumatoid arthritis who have achieved sustained low disease activity on biologic or targeted synthetic DMARDs.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.